Cole R Steber1, Ryan T Hughes2, Michael H Soike3, Travis Jacobson2, Corbin A Helis2, Joshua C Farris2, Michael K Farris2. 1. Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, NC. Electronic address: costeber@wakehealth.edu. 2. Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, NC. 3. Department of Radiation Oncology, University of Alabama-Birmingham, Birmingham, AL.
Abstract
INTRODUCTION: At our institution, stereotactic body radiotherapy (SBRT) has commonly been prescribed with 50 Gy in 5 fractions and in select cases, 50 Gy in 10 fractions. We sought to evaluate the impact of these 2 fractionation schedules on local control and survival outcomes. METHODS: We reviewed patients treated with SBRT with 50 Gy/5 fraction or 50 Gy/10 fraction for early-stage non-small cell lung cancer (NSCLC) and metastatic NSCLC. Cumulative incidence of local failure (LF) was estimated using competing risk methodology. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method only for patients with stage I disease. RESULTS: Of the 353 lesions, 300 (85%) were treated with 50 Gy in 5 fractions and 53 (15%) with 10 fractions. LFs at 3 years were 6.5% and 23.9% and Kaplan-Meier estimate of median time to LF was 17.5 months and 26.2 months, respectively. Multivariable analysis revealed increasing planning target volume (hazard ratio 1.01, P = .04) as an independent predictor of increased LF, but tumor size, ultracentral location, and 10 fractions were not. Among patients with stage I NSCLC (n = 298), overall median PFS was 35.6 months and median OS was 42.4 months. There was no difference in PFS or OS between the 2 treatment regimens for patients with stage I NSCLC. Low rates of grade 3+ toxicity were observed, with 1 patient experiencing grade 3 pneumonitis after a 5-fraction regimen of SBRT. CONCLUSION: Dose-fractionation schemes with BED10 ≥ 100 Gy provide superior local control and should be offered when meeting commonly accepted constraints. If those regimens appear unsafe, 50 Gy in 10 fractions may provide acceptable compromise between tumor control and safety with relatively durable control, and minimal negative impact on long-term survival.
INTRODUCTION: At our institution, stereotactic body radiotherapy (SBRT) has commonly been prescribed with 50 Gy in 5 fractions and in select cases, 50 Gy in 10 fractions. We sought to evaluate the impact of these 2 fractionation schedules on local control and survival outcomes. METHODS: We reviewed patients treated with SBRT with 50 Gy/5 fraction or 50 Gy/10 fraction for early-stage non-small cell lung cancer (NSCLC) and metastatic NSCLC. Cumulative incidence of local failure (LF) was estimated using competing risk methodology. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method only for patients with stage I disease. RESULTS: Of the 353 lesions, 300 (85%) were treated with 50 Gy in 5 fractions and 53 (15%) with 10 fractions. LFs at 3 years were 6.5% and 23.9% and Kaplan-Meier estimate of median time to LF was 17.5 months and 26.2 months, respectively. Multivariable analysis revealed increasing planning target volume (hazard ratio 1.01, P = .04) as an independent predictor of increased LF, but tumor size, ultracentral location, and 10 fractions were not. Among patients with stage I NSCLC (n = 298), overall median PFS was 35.6 months and median OS was 42.4 months. There was no difference in PFS or OS between the 2 treatment regimens for patients with stage I NSCLC. Low rates of grade 3+ toxicity were observed, with 1 patient experiencing grade 3 pneumonitis after a 5-fraction regimen of SBRT. CONCLUSION: Dose-fractionation schemes with BED10 ≥ 100 Gy provide superior local control and should be offered when meeting commonly accepted constraints. If those regimens appear unsafe, 50 Gy in 10 fractions may provide acceptable compromise between tumor control and safety with relatively durable control, and minimal negative impact on long-term survival.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Larry Kestin; Inga Grills; Matthias Guckenberger; Jose Belderbos; Andrew J Hope; Maria Werner-Wasik; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao; Di Yan Journal: Radiother Oncol Date: 2014-03-11 Impact factor: 6.280
Authors: Jeffrey R Olsen; Clifford G Robinson; Issam El Naqa; Kimberly M Creach; Robert E Drzymala; Charles Bloch; Parag J Parikh; Jeffrey D Bradley Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-07 Impact factor: 7.038
Authors: Meredith Giuliani; Ashwathy S Mathew; Houda Bahig; Scott V Bratman; Edith Filion; Daniel Glick; Alexander V Louie; Srinivas Raman; Anand Swaminath; Andrew Warner; Vivian Yau; David Palma Journal: Clin Lung Cancer Date: 2018-04-18 Impact factor: 4.785
Authors: Joe Y Chang; Qiao-Qiao Li; Qing-Yong Xu; Pamela K Allen; Neal Rebueno; Daniel R Gomez; Peter Balter; Ritsuko Komaki; Reza Mehran; Stephen G Swisher; Jack A Roth Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038